Two Neil Woodford FTSE 100 trades you need to know about

Neil Woodford is not afraid to make bold trades. Here’s a look at two recent FTSE 100 (INDEXFTSE: UKX) trades the portfolio manager has made.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Despite the fact Neil Woodford has experienced a period of underperformance recently, he is still one of the most popular fund managers in the UK. As a result, many investors, myself included, like to keep an eye on his trades, to see what he’s buying, or selling, in his portfolio. Today, I’m highlighting two key FTSE 100 trades the portfolio manager has made in the last few months. Should you follow his moves?

BATS is back

Midway through last year, Woodford sold his entire holding in British American Tobacco (LSE: BATS). At the time, the sale made sense to me, as the stock had enjoyed a super run and gained 60% in just three years. With a P/E ratio of 23 and a yield of 3%, there wasn’t much value left on the table.

However, sentiment can change quickly in the stock market, and over the course of the next 18 months, BATS shares declined around 35% as investors lost interest in the tobacco sector. With the stock having returned to a more attractive valuation, Woodford has reintroduced it back into his portfolios and at 31 July, it had a 1.5% weighting in his Equity Income fund. A good move?

I think this is a great trade. At current levels, BATS offers considerably more value than it did in early 2017. It’s current forward P/E of 13 is much more appropriate for a tobacco stock and the prospective yield of 5.2% looks quite attractive.

Of course, with smoking rates declining across the Western world, there are risks to the investment case. Yet with the acquisition of Reynolds American under its belt, BATS looks to have the firepower to continue prospering and paying big dividends, in my view.

Legal & General has disappeared

Another interesting Woodford trade is the removal of Legal & General Group (LSE: LGEN) from the Equity Income fund. In the recent past, this has been one of Woodford’s top holdings. Yet all of a sudden, it’s been removed from the portfolio with very little explanation. This has surprised a few investors, with several voicing their concerns over the sale of the stock as well as the lack of transparency, on Woodford’s website.

Digging deeper, Woodford Investment Management analyst Anton Balint provides a very short explanation of the sale in the comments section of the website, stating: “Legal & General’s fundamental attractions, such as its cash generative quality and healthy dividend stream, remain very much in place. However, Neil views each position in the portfolios he manages from a relative valuation basis perspective – this means that some businesses can become more undervalued than others from time to time.

In other words, Woodford sees more value elsewhere right now. But was he right to remove the stock entirely from his portfolio? Personally, I’m a little confused by this trade – especially given the fact Woodford’s fund is meant to be an ‘income’ fund.

I continue to see a lot of attraction in Legal & General from an income investing point of view. Recent results showed that the group has momentum, with five of its six businesses increasing their operating profits for the first half of 2018, and the stock’s P/E of 8.9 and dividend yield of 6.4% look attractive, to my mind. I own LGEN in my own dividend portfolio and I have no intention of selling any time soon. 

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Edward Sheldon owns shares in Legal & General Group. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »